

Form 1449

U.S. Department of Commerce
Patent and Trademark Office

ATTY. DOCKET NO.
2444-101

SERIAL NO.
09/601,444

LIST OF MATERIALS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT
Esther H. CHANG et al.

FILING DATE
02 August 2000

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO


NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Q	Aoki, K et al. "Liposome-mediated <i>in Vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity", <i>Cancer Research</i> , Sept. 1, 1995; 55:3810-3816
	Dzau, V.J. et al. "Fusigenic viral liposome for gene therapy in cardiovascular diseases", <i>Proc. Natl. Acad. Sci. USA</i> , October 1996; 93:11421-11425
	Feero, W.G. et al. "Selection and use of ligands for receptor-mediated gene delivery to myogenic cells", <i>Gene Therapy</i> , 1997; 4:664-674
	Filion, M.C. et al. "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells", <i>Biochimica et Biophysica Acta</i> , 1997; 1329:345-356
	Grimaldi, S. et al. "Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection", <i>Res. Virol.</i> , 1997; 148:177-180
	He, Y. et al. "Growth Inhibition of Human Papillomavirus 16 DNA-positive Mouse Tumor by Antisense RNA Transcribed from U6 Promoter", <i>Cancer Research</i> , September 15, 1997; 57:3993-3999
	Lappalainen, K. et al. "Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells", <i>Antiviral Research</i> , 1994; 23:119-130

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449	U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. 2444-101	SERIAL NO. 09/601,444		
LIST OF MATERIALS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Esther H. CHANG et al.				
		FILING DATE 02 August 2000	GROUP			
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
B	Lavigne, C. et al. "Enhanced Antisense Inhibition of Human Immunodeficiency Virus Type 1 in Cell Cultures by DLS Delivery System", <i>Biochemical and Biophysical Research Communications</i> , 1997; 237:566-571					
	Lee, R.J. et al. "Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer", <i>The Journal of Biological Chemistry</i> , April 5, 1996; 271(14):8481-8487					
	Morishita, R. et al. "Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer", <i>J. Cardiovasc. Pharmacol. Therapeut.</i> , 1996; 2(3):213-222					
	Plank, C. et al. "Activation of the Complement System by Synthetic DNA Complexes: A Potential Barrier for Intravenous Gene Delivery", <i>Human Gene Therapy</i> , Aug. 1, 1996; 7:1437-1446					
	Renneisen, K. et al. "Inhibition of Expression of Human Immunodeficiency Virus-1 <i>in Vitro</i> by Antibody-targeted Liposomes Containing Antisense RNA to the <i>env</i> Region", <i>The Journal of Biological Chemistry</i> , Sept. 25, 1990; 265(27):16337-16342					
	Ropert, C. et al. "Oligonucleotides Encapsulated in pH Sensitive Liposomes are Efficient Toward Friend Retrovirus", <i>Biochemical and Biophysical Research Communications</i> , Mar. 16, 1992; 183(2):879-885					
	Seth, P. et al. "Adenovirus-mediated Gene Transfer to Human Breast Tumor Cells: An Approach for Cancer Gene Therapy and Bone Marrow Purging", <i>Cancer Research</i> , Mar. 15, 1996; 56:1346-1351					
	Wagner, E. et al. "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle", <i>Proc. Natl. Acad. Sci. USA</i> , Sept. 1992; 89:7934-7938					
	Xu, M. et al. "Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity", <i>Human Gene Therapy</i> , Jan. 20, 1997; 8:177-185					
	Zelphati, O. et al. "Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes", <i>Antiviral Research</i> , 1994; 25:13-25					
	Zelphati, O. et al. "Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms", <i>Nucleic Acids Research</i> , 1994; 22(20):4307-4314					
EXAMINER						
		DATE CONSIDERED				
		7/9/02				
EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

#7

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Complete if Known

Application Number	09/601,444
Filing Date	January 4, 2001
First Named Inventor	Esther H. Chang
Group Art Unit	1632
Examiner Name	Dave Trong Nguyen

Sheet

of

1

Attorney Docket Number 2444-101

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	AA	6,071,533		Papahadjopoulos et al.	06-06-2000

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			

Examiner
Signature

Date
Considered

7/1/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.